24 Androgen receptor (AR) expression in triple negative breast cancer (TNBC): results from a phase II neoadjuvant trial with carboplatin and eribulin mesylate in TNBC patients

for 57+ weeks. At the RD (n = 14): mean (SD) clearance (CL) 18.1 (7.2) L/h; AUC 318 (123) h·mg/L; Cmax 90.5 (30.7) mg/L; t1/2 30.5 (13.6) h. No apparent association between CL and DLT or magnitude of neutropenia was found. Conclusions: The RD of PM01183 is 5mg FD on D1&8 q3wk. At this RD, myelosuppression led to frequent dosing delays or omissions, but G-CSF support enabled the targeted dose intensity in some individuals. Two patients had prolonged disease stabilization lasting over a year. No signs of cumulative toxicity were observed. Interindividual variability in CL was high, but did not appear to be associated with toxicity.